Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Yong Ben is Chief Med & Dev Officer at Bridgebio Oncology Therapeutics. OQRO lists 5 transactions filed with the SEC under this name, the latest on Oct 6, 2026, each linked to the official Form 4.
Chief Med & Dev Officer
Disclosures on record
5
Companies involved
1
Bridgebio Oncology TherapeuticsBBOT
5 disclosures · Mar 2026 – Oct 2026
Oct 1, 20261,047disclosed Oct 6
DetailsOfficial recordJul 1, 20261,047disclosed Jul 7
DetailsOfficial recordApr 1, 20261,047disclosed May 6
DetailsOfficial recordMar 10, 202647Kdisclosed Mar 13
DetailsOfficial recordMar 10, 2026210Kdisclosed Mar 13
DetailsOfficial recordAs of the latest filing on , Yong Ben reported holding 43,529 shares of Bridgebio Oncology Therapeutics (BBOT), worth about $79K at the last close of $2 (Nov 18, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Bridgebio Oncology Therapeutics BBOT | 43,529 | 44K direct | $2 | $79K | Oct 1, 2026 |
Is this Yong Ben’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 1, 2026, Yong Ben reported holding 43,529 shares of Bridgebio Oncology Therapeutics (BBOT). At the last close of $2 on Nov 18, 2026, that is about $79K. This is the stake disclosed in filings, not a net worth.
No public filing gives Yong Ben's net worth. What SEC Form 4 shows is the stock stake: 43,529 shares of Bridgebio Oncology Therapeutics (BBOT), about $79K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.